A clinical-stage company developing a medicinal product for the European market required a regulatory submission strategy alongside a strategic HTA roadmap and execution framework for Europe. Financial headwinds delayed HTA activities, creating a material sequencing risk for the European development programme.

therainnova led the regulatory strategy throughout an ongoing financing period while coordinating with an external HTA specialist partner to co-develop the client`s HTA strategy and execution framework. Following the investment close, therainnova supported the restructuring of the European development roadmap and HTA sequencing, establishing a robust path and timeline for progressing toward European registration and reimbursement.

Maintaining strategic programme continuity through a financing gap - protecting asset value, preserving development optionality, and enabling the company to proceed toward EU registration and reimbursement.